Stenberg TA, Kildal AB, How OJ, Myrmel T. Adrenomedullinepinephrine cotreatment enhances cardiac output and left ventricular function by energetically neutral mechanisms. Am J Physiol Heart Circ Physiol 302: H1584 -H1590, 2012. First published February 3, 2012 doi:10.1152/ajpheart.00887.2011.-Adrenomedullin (AM) used therapeutically reduces mortality in the acute phase of experimental myocardial infarction. However, AM is potentially deleterious in acute heart failure as it is vasodilative and inotropically neutral. AM and epinephrine (EPI) are cosecreted from chromaffin cells, indicating a physiological interaction. We assessed the hemodynamic and energetic profile of AM-EPI cotreatment, exploring whether drug interaction improves cardiac function. Left ventricular (LV) mechanoenergetics were evaluated in 14 open-chest pigs using pressure-volume analysis and the pressure-volume area-myocardial O 2 consumption (PVA-MV O2) framework. AM (15 ng·kg Ϫ1 ·min Ϫ1 , n ϭ 8) or saline (controls, n ϭ 6) was infused for 120 min. Subsequently, a concurrent infusion of EPI (50 ng·kg Ϫ1 ·min Ϫ1 ) was added in both groups (AM-EPI vs. EPI). AM increased cardiac output (CO) and coronary blood flow by 20 Ϯ 10% and 39 Ϯ 14% (means Ϯ SD, P Ͻ 0.05 vs. baseline), whereas controls were unaffected. AM-EPI increased CO and coronary blood flow by 55 Ϯ 17% and 75 Ϯ 16% (P Ͻ 0.05, AM-EPI interaction) compared with 13 Ϯ 12% (P Ͻ 0.05 vs. baseline) and 18 Ϯ 31% (P ϭ not significant) with EPI. LV systolic capacitance decreased by Ϫ37 Ϯ 22% and peak positive derivative of LV pressure (dP/dt max) increased by 32 Ϯ 7% with AM-EPI (P Ͻ 0.05, AM-EPI interaction), whereas no significant effects were observed with EPI. Mean arterial pressure was maintained by AM-EPI and tended to decrease with EPI (ϩ2 Ϯ 13% vs. Ϫ11 Ϯ 10%, P ϭ not significant). PVA-MV O2 relationships were unaffected by all treatments. In conclusion, AM-EPI cotreatment has an inodilator profile with CO and LV function augmented beyond individual drug effects and is not associated with relative increases in energetic cost. This can possibly take the inodilator treatment strategy beyond hemodynamic goals and exploit the cardioprotective effects of AM in acute heart failure.
cardioprotective effects are therapeutically attractive, and the hemodynamic profile of AM is advantageous in experimental heart failure models (35) . The hypotensive effect, however, is possibly detrimental in ischemic heart failure, and profound hypotension after AM administration to patients with acute myocardial infarction has been reported (16) .
Interestingly, AM and catecholamines are both secreted from chromaffin cells through Ca 2ϩ -dependent regulated exocytosis after cholinergic stimulation (17) . Adrenal medullary basal catecholamine release and catecholamine levels in plasma are both increased by AM (1, 43) , whereas AM release from chromaffin cells is augmented by dibutyryl cAMP, a membrane-permeable analog of cAMP (21) . AM release from cultured rat vascular smooth muscle cells is also augmented by epinephrine (EPI) (40) . Thus, there is evidence indicating a physiological interaction between AM and catecholamines such as EPI. Furthermore, cAMP is a well-recognized second messenger in AM signal transduction, and both negative and positive modulation of ␤-adrenergic signaling by AM has been reported in vitro (10, 13) . It is presently unknown whether AM can modulate hemodynamic and inotropic responses to ␤-adrenergic stimulation in vivo.
In addition to hemodynamic and potentially cytoprotective effects, AM appears to be involved in insulin regulation, fatty acid mobilization, and glucose metabolism (13, 26) . These metabolic effects of AM, either alone or in combination with EPI, can potentially influence left ventricular (LV) energetics due to alterations in the concentration of free fatty acids in plasma (23) . There is evidence indicating that AM has favorable energetic properties (29) , but the relation between total mechanical work and myocardial O 2 consumption (MV O 2 ) has not been quantified.
In the present study, we assessed the hemodynamic and contractile effects of potentially therapeutic levels of AM in a porcine model. In addition, we analyzed whether low-dose AM infusion modulates the hemodynamic and contractile effects of ␤-adrenergic stimulation by a low-dose EPI infusion in physiologically intact animals. The effects of both individual and combined treatments on LV energetics were quantified through the assessment of total mechanical work and MV O 2 within the pressure-volume area (PVA)-MV O 2 framework.
METHODS
The experimental protocol was approved by the local steering committee of the Norwegian Animal Research Authority and was conducted in compliance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals (1996) . Fourteen castrated male pigs (Norwegian Landrace, Sus scrofa domesticus) weighing 27 Ϯ 2 kg were habituated to the animal facilities for 4 -7 days and fasted overnight before the experiment with free access to water. The premedication, anesthetic protocol, surgical preparation of the open-chest model, conductance volumetric technique, and LV energetic assessment method have been previously detailed (28) .
Instrumentation. Animals were anesthetized, tracheostomized, and ventilated via a volume-controlled ventilator (Servo 900 D, ElemaSchönander). A 7-Fr balloon catheter for preload reductions and transient caval occlusions was placed in the inferior caval vein. The hemiazygos vein was ligated to avoid mixture of systemic blood into the coronary sinus. Transit-time flow probes (Medi-Stim PB series, Medi-Stim) were placed on the pulmonary trunk, coronary, left femoral, and left carotid arteries for measurements of CO, coronary blood flow (CBF), muscular blood flow, and cerebral blood flow. The great cardiac vein was catheterized through the superior caval vein and coronary sinus for blood sampling. A 7-Fr dual-field combined pressure-conductance catheter (CD Leycom) was inserted into the LV via the right carotid artery to measure LV volume and pressure. Intravascular volume was maintained with a glucose-enriched (1.25 g/l) saline infusion (20 ml·kg Ϫ1 ·h Ϫ1 ). Animals received 150 mg amiodaron to prevent arrhythmias, and 2,500 IE heparin was administered to prevent catheter clotting.
Experimental protocol. In preliminary experiments, the porcine dose-response relationship to intravenous infusions of human AM 1-52 (10 -150 ng·kg Ϫ1 ·min Ϫ1 , Bachem) was established ( Fig. 1 ). Low-dose AM (15 ng·kg Ϫ1 ·min Ϫ1 ) was chosen to achieve a moderate increase in CO while minimizing heart rate (HR) and mean arterial pressure (MAP) alterations, thus aiming at a potentially tolerable level in settings with acute ischemia and hemodynamic instability.
The isolated effect of AM and the interaction between AM and a concurrent infusion of EPI (AM-EPI) were compared with the individual effect of EPI in a time-matched control group receiving saline as vehicle. After baseline measurements, the AM group (n ϭ 8) received a continuous infusion of AM, whereas the control group (n ϭ 6) received a continuous infusion of saline. A second set of measurements was obtained 120 min after baseline recordings. Subsequently, both groups received a concurrent infusion of EPI (50 ng·kg Ϫ1 ·min Ϫ1 ) with the third set of measurements obtained at steady state (ϳ15 min).
LV energetics. LV MV O2 was plotted as a function of PVA as described by Suga (39) . The PVA-MV O2 relation at each measurement set was assessed by preload alteration and differing levels of steady-state LV mechanical work. MAP and CBF were allowed to reach uninfluenced levels between the successive preload reductions to ensure unimpaired LV function. At each preload, steady-state pressure-volume data were recorded for 10 s with simultaneous blood sampling from the great cardiac vein to calculate cardiac O2 extraction. PVA and MV O2 were calculated as previously described (28) .
LV function and ventriculoarterial matching. Indexes of global LV function [preload recruitable stroke work (PRSW)], inotropy [slope (E es) and volume axis intercept (V0) of the end-systolic pressurevolume relationship (ESPVR)], and lusitropy [curve fitting constant (␣) and diastolic stiffness constant (␤) of the end-diastolic pressurevolume relationship (EDPVR)] derived from the pressure-volume loops were evaluated by transient caval occlusions, whereas indexes derived at steady state [peak positive and negative derivatives of LV pressure (dP/dt max and dP/dtmin, respectively), and isovolumic time constant ()] were assessed using the initial steady-state recording at each measurement set. PRSW, which incorporates both systolic and diastolic properties, is a relatively load-insensitive index of global LV function (9) . The ESPVR was defined as follows: ESP ϭ E es(ESV Ϫ V0), where ESP and ESV are end-systolic pressure and volume, respectively. The EDPVR was defined by the following exponential relation: EDP ϭ ␣e (␤EDV) where EDP and EDV are end-diastolic pressure and volume, respectively. Due to covariance between Ees and V0, as well as nonlinearities in the ESPVR, positive inotropic effects may manifest as increased slope (Ees) or a leftward ESPVR shift (V0). Importantly, with the EDPVR being nonlinear in nature, there is no agreed upon method to compare EDPVRs without logarithmic transformation (3). Calculating capacitance yields variables that reflect altered LV function by integrating altered slope (E es and ␤) and/or shifts in the intercept (V0 and ␣) (37) . LV systolic capacitance (ESV120) and LV diastolic capacitance (EDV20) were defined as follows: ESV120 ϭ (120/Ees) ϩ V0 and EDV20 ϭ [ln(20/␣)]/␤. Arterial elastance (Ea) was calculated as follows: ESP/stroke volume. Systemic vascular resistance (SVR) was calculated as mean systemic perfusion pressure/CO and expressed as dyn·s·cm Ϫ5 . Ventriculoarterial (VA) matching was assessed by the ratios of Ea/Ees and PRSW/ SVR (12) .
Statistics. Groups and drug interactions were assessed by two-way repeated-measurements ANOVA (least-squares linear regression with dummy variables, subject identifier as random effect). Pooled PVA-MV O2 data were analyzed by two-way repeated-measurements analysis of covariance (ANCOVA; dummy variables and random effect as above). Tukey's highly significant difference test was used to adjust for multiple comparisons, and P values of Ͻ0.05 were considered statistically significant. Statistical analysis was performed using JMP 7 (SAS Institute) with absolute or relative data (i.e., percent change from baseline) consistent with the data presented. Values are reported as means Ϯ SD.
RESULTS
The hemodynamic variables were matched between groups at baseline with the exception of a higher HR in the control group (62 Ϯ 7 vs. 88 Ϯ 6 beats/min, P Ͻ 0.05). LV systolic and diastolic function, LV energetics, and VA matching were similar in both groups at baseline. Hemodynamic and LV functional data are shown as percent changes from baseline values in Fig. 2 . Corresponding absolute data and PVA-MV O 2 parameters are shown in Tables 1-3 .
LV function and VA matching. The effects of AM, EPI, and AM-EPI on LV function are shown in Figs. 2 and 3 . LV function, as assessed by dP/dt max , showed that AM alone had no observable effect on contractility. AM-EPI increased dP/ dt max by 32 Ϯ 14% compared with baseline (P Ͻ 0.05), whereas the control group had an initial Ϫ14 Ϯ 12% decrease with saline (P Ͻ 0.05) and with EPI dP/dt max was still Ϫ2 Ϯ 14% [P ϭ not significant (NS)] compared with baseline. Interaction analysis showed a significant interaction with AM-EPI (P Ͻ 0.05). Global LV function, as measured by PRSW, showed that AM had no effect on LV function when administered alone. With AM-EPI, PRSW increased by 40 Ϯ 14% compared with baseline values (P Ͻ 0.05), whereas EPI alone produced a nonsignificant 23 Ϯ 27% increase. Through interaction analysis using absolute data, an interaction between AM-EPI was observed (P Ͻ 0.05; Table 2 ). ESV 120 decreased by Ϫ37 Ϯ 22% with AM-EPI compared with baseline (P Ͻ 0.05), whereas it was unaltered with the individual drugs (19 Ϯ 18% vs. 16 Ϯ 42%, AM vs. EPI, P ϭ NS). The effect of AM-EPI cotreatment was a greater reduction in ESV 120 compared with EPI infusion in the control group, and a significant interaction was detected (P Ͻ 0.05; Fig. 2 and Table 2 ).
VA matching was assessed using the ratios of E a /E es and PRSW/SVR. Afterload, as assessed by E a , predominantly reflecting arterial compliance, showed no systematic changes. The ratio of E a /E es was unaltered across all conditions. SVR primarily reflects peripheral vasoconstriction, and, in contrast to E a , SVR was reduced with AM, EPI, and AM-EPI (Ϫ14 Ϯ 13%, Ϫ23 Ϯ 10%, and Ϫ34 Ϯ 14%, P Ͻ 0.05 vs. baseline by one-way ANOVA). The ratio of PRSW/SVR increased with AM, EPI, and AM-EPI (22 Ϯ 18%, 58 Ϯ 44%, and 120 Ϯ 41%, P Ͻ 0.05). A significant interaction was detected with PRSW/SVR, and thus forward flow facilitation was augmented to a greater extent by AM-EPI than by the individual drugs (P Ͻ 0.05).
AM-EPI / EPI
AM-EPI / EPI AM-EPI / EPI Values are means Ϯ SD; n ϭ 8 animals in the adrenomedulin (AM) group and 6 animals in the control group. EPI, epinephrine; AM-EPI, AM and EPI cotreatment; Ea, arterial elastance; SVR, systemic vascular resistance. Within-group differences: *P Ͻ 0.05 vs. baseline and †P Ͻ 0.05 vs. AM or control; between-group differences: ‡P Ͻ 0.05; interaction: §P Ͻ 0.05 (by two-way repeated-measures ANOVA).
LV energetics. PVA-MV O 2 relationships within each group are shown as pooled scatterplots in Fig. 4 . Mean PVA-MV O 2 parameters are shown in Table 3 . There was no observable effect on the slope (i.e., cardiac energetic efficiency) or y-intercept (i.e., unloaded MV O 2 ) of the PVA-MV O 2 relationship with AM, EPI, or AM-EPI. Individual slope and y-intercept values showed no significant between-or within-group differences, and repeated-measurements ANCOVA of pooled PVA-MV O 2 data showed no significant main or interaction effects. Thus, LV energetics were unaffected by AM, EPI, or AM-EPI.
DISCUSSION
Our study supports evidence suggesting physiologically relevant interactions between AM, ␤-adrenergic signaling, and the sympathetic nervous system. As stated, an interrelationship between the signaling and release of AM and catecholamines has been observed in several models (1, 40, 43) , and modulation of ␤-adrenergic signaling has been reported (10, 13) . In addition, increased sympathetic activity has been seen with intravenous administration of AM (36) . However, whether cotreatment could produce hemodynamically relevant interaction effects has not been previously described. Our data show that the increase in CO is paralleled by a chronotropic response, and altered HR could potentially explain the increased contractility observed with AM-EPI. However, a higher absolute HR was seen in the control group at baseline, and with AM-EPI and EPI, the HR was similar between groups, thereby indicating that other mechanisms are responsible for the increase in LV systolic function during AM-EPI cotreatment.
AM can enhance the baroreceptor reflex response through cAMP-and PKA-dependent signaling in the nucleus tractus solitarius, the terminal site for primary baroreceptor afferents (11) . Increased HR and cardiac sympathetic nerve activity have also been reported, with the effect being more pronounced with AM than with pressure-matched nitroprusside administration (4). Interestingly, the inotropic effect of CGRP has been attributed to indirect myocardial sympathetic activation through an increased interstitial concentration of norepinephrine (18) . AM belongs to the CGRP peptide superfamily and partly shares receptor complexes with calcitonin receptor-like receptor (CL) and receptor activity-modifying protein (RAMP)2 and RAMP3, which constitute AM receptors, whereas CL and RAMP1 form the CGRP receptor (15) . To which extent AM may stimulate myocardial sympathetic signaling remains to be clarified. Adrenal chromaffin cells used as models of catecholaminereleasing neurons have been shown to release AM through cAMP-mediated mechanisms (22) , and catecholamine release after AM administration has also been reported (1) . Thus, a hypothetical feedback system regulating myocardial sympathetic activity may be envisioned.
AM reduces E a and SVR and affects potent vasodilation in resistance vessels (6, 24, 34) , whereas preload is maintained (24) . Thus, in addition to the chronotropic response, reduced afterload with concomitantly less effect on capacitance vessels and sustained venous return may also explain why AM potently augments CO. It is uncertain whether AM has inotropic properties in vivo as there are reports of both positive and unaltered inotropy (24, 29) . Positive inotropic effects in vivo (24); thus, AM is probably inotropically neutral within the potentially therapeutic dose range. We found no evidence of any inotropic effect with low-dose AM, and preliminary dose-response experiments revealed no inotropic effect with doses ranging from 10 to 150 ng·kg Ϫ1 ·min Ϫ1 (data not shown). AM-EPI cotreatment caused moderate elevations of dP/dt max and PRSW, with both being larger than with EPI as the only active drug, and a significant AM-EPI interaction was thus observed. The ESPVR was unaltered, as assessed by E es and V 0 , and there were no differences in ␣ or ␤ describing the EDPVR. The calculation of systolic capacitance accounts for the potential covariance between E es and V 0 (3, 37) , and the reduction in ESV 120 with AM-EPI exceeded the sum of the individual drug effects, thus implying that the end-systolic stiffness (i.e., contractility) was increased through AM-EPI interaction. As shown in Fig. 3 , AM-EPI produced a leftward shift of the ESPVR together with increased E es , thereby indicating an improved contractile performance within the measured pressure range. The functional parameters dP/dt max , PRSW, and ESV 120 were unaltered by AM, thereby indicating that the interaction effect is synergistic in nature.
AM is metabolically active and confers lipolytic properties in vitro (13) , and catecholamines and sympathomimetic drugs are known to increase free fatty acids in plasma (27) . Combining lipolytic drugs that can increase free fatty acids in plasma could potentially induce a mechanoenergetic inefficiency that would be unwanted therapeutically in the ischemically challenged heart (23) . This is the first study to characterize LV energetics using total mechanical work related to MV O 2 with systemic administration of AM. Favorable energetic properties of AM have been reported with an increase in contractility paralleling a reduction in MV O 2 , thus implying an increased mechanoenergetic efficiency (29) . However, afterload reduction and relatively less energetic cost with volume versus pressure work may explain the finding, and the relationship between total mechanical work and MV O 2 must be assessed to describe any influence on LV energetics (39) . We found no evidence of altered mechanoenergetic efficiency or unloaded MV O 2 with AM, EPI, or AM-EPI.
The vascular response after AM administration is heterogeneous with increased blood flow in the heart, lungs, kidneys, adrenal glands, and spleen, whereas the splanchnic bed is relatively unaffected (19) . In agreement with earlier studies (7, 44) showing that AM infusion augments CBF, we found that low-dose AM produced a relatively large increase in CBF. This effect was further enhanced by AM-EPI cotreatment, and the extent of CBF elevation suggests that the drugs interact. Importantly, PVA-MV O 2 data indicate that the observed increase is not metabolically induced, as unloaded MV O 2 , contractile efficiency, and total mechanical work were similar between groups. In vitro studies (2, 42) have shown that AM AM-EPI mediates coronary vasodilation through nitric oxide (NO) synthase (NOS) and EDHF pathways. In the isolated rat aorta, AM causes endothelium-dependent vasodilation by Ca 2ϩ -mediated activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway, which, in turn, activates endothelial NOS (eNOS) and NO production (32) . In endothelial cells, cAMP accumulation and mobilization of intracellular Ca 2ϩ stores via phospholipase C and inositol 1,4,5-trisphosphate formation have been observed after AM exposure (38) . In addition to PI3K activation, increased levels of intracellular Ca 2ϩ in endothelial cells can also produce vasodilation through the EDHF pathway with opening of endothelial small-and intermediate-conductance Ca 2ϩ -activated K ϩ channels inducing hyperpolarization of vascular smooth muscle (8) . Interestingly, NO production in canine myocardial microvessels after exposure to AM or isoproterenol is substantially enhanced in subjects with heart failure despite eNOS downregulation, an effect abolished by NOS, PKA, and PI3K inhibition (45) . Thus, cAMP and PI3K appear to serve as compensatory pathways that can sustain or augment NO production in situations with eNOS downregulation and endothelial dysfunction. Furthermore, as both pathways have been implicated in AM and ␤-adrenergically induced vasorelaxation (45), they could potentially serve to explain the substantial augmentation of CBF observed with AM-EPI cotreatment.
Conclusions. The main observations presented in this study is that low-dose AM is inotropically neutral and increases CO primarily through vasodilation and chronotropy, that low-dose AM-EPI cotreatment has the hemodynamic profile of an inodilator with CO and LV function augmented beyond individual drug effects, and that this functional enhancement is not associated with disproportionate increases in energetic expenditure.
Thus, low-dose AM-EPI cotreatment has a hemodynamic profile that is attractive in ischemic heart failure and circulatory compromise with cardiac unloading, increased CO and inotropy, maintained systemic perfusion pressure, and mechanoenergetic neutrality. In addition, AM is potentially attractive in settings of ischemia and heart failure due to its effect on infarct size, arrhythmias, and mortality. In combination with an inotrope, this can take the inodilator treatment strategy beyond purely hemodynamic goals by exploiting the pleiotropic effects while supporting the circulation with an inotrope. The chronotropic effect of AM-EPI, however, is a concern in acute heart failure and should be evaluated in future studies.
